Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiObex has secured a critical patent from the US Patent and Trademark Office for the use of very low dose glucagon, or DIO-901, in the prevention of insulin-induced hypoglycemia in diabetes patients.
Subscribe to our email newsletter
The patent grants DiObex exclusive rights to methods of reducing the risk of hypoglycemia in diabetes patients being treated with insulin by administering very low doses of glucagon.
DIO-901 is expected to begin Phase II clinical testing later in 2008 and has received fast track status from the FDA, underscoring the great unmet medical need in the prevention of insulin-induced hypoglycemia.
David Cory, CEO of DiObex, said: “DIO-901 is the only therapeutic in development to prevent insulin-induced hypoglycemia, which is known to limit optimal glycemic control and cause recurring medical complications in most people with type 1 diabetes, in many with type 2 diabetes, and is sometimes fatal.”